Searchable abstracts of presentations at key conferences in endocrinology

ea0026p64 | Endocrine tumours and neoplasia | ECE2011

Primary hyperparathyroidism in MEN1 patients: preferred surgical procedure and relation with genotype

Pieterman C R C , van Hulsteijn L T , den Heijer M , van der Luijt R B , Hermus A R M M , Vriens M R , Valk G D

Background: Primary hyperparathyroidism (pHPT) is the most prevalent manifestation of multiple endocrine neoplasia type 1 (MEN1). Surgery is the preferred treatment but which type of surgery offers the best chance of cure combined with the lowest risk of postoperative hypoparathyroidism is still uncertain.Aims: Identifying the optimal surgical technique for MEN1 related pHPT. Describing the course of postoperative hypoparathyroidism. To see if a genotype...

ea0026p456 | Thyroid cancer | ECE2011

Thr300Ala ATG16L1 polymorphism influences susceptibility to and the prognosis of epithelial cell derived thyroid carcinoma

Huijbers A , Plantinga T S , Oosting M , Joosten L A B , Aben K K H , Netea M G , Hermus A R M M , Netea-Maier R T

Background: Loss of autophagy protein ATG16L1 enhances endotoxin-induced interleukin 1β (IL1β) production. IL1β has been found to have antineoplastic effects in thyroid malignancies. We hypothesized that a missense polymorphism in ATG16L1 autophagy gene (Thr300Ala) results in changes in the function of the molecule and influences susceptibility to and prognosis of epithelial cell derived thyroid carcinoma (TC).Objective: i) To assess the f...

ea0026p237 | Pituitary | ECE2011

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma M R , Netea-Maier R T , van den Berg G , Homan J , Sluiter W J , van den Bergh A C M , Wolffenbuttel B H R , Hermus A R M M , van Beek A P

Objective: To assess the influence of use of long-acting somatostatin analogs on long-term health-related quality of life (HR-QoL) in relation to disease control in patients surgically-treated for acromegaly.Design: Cross-sectional study in two University Medical Centers in The Netherlands.Patients: One hundred and eight patients (47 m/61 f, mean age 54±11 years) with a minimal follow up period of 1 year after pituitary surger...